<DOC>
	<DOC>NCT01084655</DOC>
	<brief_summary>This is an open-label, multicenter, Phase 1/2 study of TAK-700 in combination with docetaxel and prednisone that will evaluate the safety and pharmacokinetics (PK) of the combination and will allow estimation of prostate-specific antigen (PSA) response in men with metastatic castration-resistant prostate cancer (mCRPC).</brief_summary>
	<brief_title>Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Each patient must meet all of the following inclusion criteria: Voluntary written consent Male patients 18 years or older Estimated life expectancy of 6 months or more Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma Radiographdocumented metastatic disease Progressive disease Prior surgical castration or concurrent use of an agent for medical castration Eastern Cooperative Oncology Group (ECOG) performance status 02 Physical examination findings that are consistent with other study entry or exclusion criteria and identified but not excluded chronic conditions Even if surgically sterilized, patients must Practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug, OR Abstain from heterosexual intercourse Any use of opiates must be stable for at least 2 weeks prior to study entry Meet screening laboratory values as specified in protocol Suitable venous access Patients meeting any of the following exclusion criteria are not to be enrolled in the study: Known hypersensitivity to TAK700, docetaxel, prednisone or related compounds Received any of the following within 30 days prior to the first dose of TAK700: prior therapy with any investigational compound; prior herbal product known to decrease PSA; OR radiation therapy for prostate cancer Received prior therapy with TAK700, aminoglutethimide, ketoconazole or abiraterone (for Phase 1 only, patients previously treated with ketoconazole or abiraterone will be eligible if treatment with ketoconazole or abiraterone was discontinued at least 30 days prior to enrollment) Received antiandrogen therapy within 4 weeks for flutamide and 6 weeks for all others prior to first dose of study drug Received prior chemotherapy for prostate cancer Current spinal cord compression, bilateral hydronephrosis or neck outlet obstruction Symptoms that investigator deems related to prostate cancer Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected Uncontrolled cardiovascular condition New York Heart Association Class (NYHA) Class III or IV Uncontrolled hypertension despite medical therapy Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C Unwilling or unable to comply with protocol Major surgery or serious infection within 14 days of first dose of TAK700 Lifethreatening illness unrelated to cancer Uncontrolled nausea, vomiting or diarrhea Known gastrointestinal disease or procedure that could interfere with oral absorption or tolerance of TAK700</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>